Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLU-Q-PAN H7N9 Formulation 3 + AS03B
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
FLU-Q-PAN H7N9 Formulation 3 + AS03B is a monovalent, inactivated, split-virion influenza vaccine candidate developed by GSK for pandemic preparedness. It targets the H7N9 subtype of Influenza A virus, specifically utilizing the A/Hong Kong/125/2017-like strain. The 'Formulation 3' designation refers to a specific antigen concentration (typically 15 µg of hemagglutinin) evaluated in clinical trials such as NCT03318315. The vaccine is formulated with the AS03B adjuvant system, which is a half-dose version of GSK's proprietary AS03 oil-in-water emulsion (containing squalene, alpha-tocopherol, and polysorbate 80). AS03 is designed to enhance the immune response, allowing for dose-sparing of the viral antigen during a pandemic by inducing higher titers of neutralizing antibodies and promoting a broader immune response.
- Brand names
- FLU-Q-PAN
- Other names
- H7N9 vaccine + AS03Bmonovalent inactivated H7N9 vaccineA/Hong Kong/125/2017-like (H7N9) vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on FLU-Q-PAN H7N9 Formulation 3 + AS03B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLU-Q-PAN H7N9 Formulation 3 + AS03B.